Abstract
The eye damage in the children presenting with atopic dermatitis is known to occur in 20-40% of the cases. The nonspecific nature of the ophthalmological symptoms of this pathology markedly complicates differential diagnostics and the choice of the pathogenetically-based therapeutic modalities. This article describes the clinical cases that demonstrate the seriousness of this problem and illustrate the necessity of the comprehensive interdisciplinary approach to its solution. It is concluded that the use of the “Restasis” pharmaceutical for the treatment of dry eye syndrome associated with atopic dermatitis in the young patients is justified as contributing to a stable remission of the disorder and producing no undesirable side effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
